Marco Meglio

Results of the phase 2 study support continued dose escalation of SRP-5051 and further clinical development.

Inclusion of measures of other factors that may influence modified cerebral Functional System Score, such as pain, and sleep quality and insomnia, were noted for future research.

Complete results of the study are expected to be published in early 2021 in a peer reviewed neurology journal.

Eric Segal, MD, director of pediatric epilepsy, HMH Hackensack University Medical Center, detailed his study on diazepam nasal spray in patients with and without antiseizure medications.

Data used from the ENSEMBLE PLUS study showed a comparable frequency of infusion reactions between those who received the 2-hour infusion and the 3.5-hour infusion.

The StrokeViewer tool is currently in use in Australia and Europe and has led to reduced patient disability in the short-term and more clot removals performed.

Future studies are necessary to determine whether longer treatment of ezogabine can sustain the effects on excitability and slow disease progression.

Kelly Knupp, MD, pediatric neurologist and epilepsy specialist, Children’s Hospital Colorado, detailed the findings of fenfluramine in patients with Lennox-Gastaut syndrome and how it may shake up the treatment landscape.

Treatment effects in favor of digital cognitive behavioral therapy were observed for insomnia severity, sleep efficiency, cognitive failures, fatigue, sleepiness, depression, and anxiety.

Patients receiving perampanel in combination with an enzyme-inducing anti-seizure medication may require a higher perampanel dose to achieve similar efficacy with only non-EIASMs.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases detailed the collaborative effort needed to see sustainable change in the approval system of neurological devices.

Christian Meisel, MD, PhD, department of neurology, Universitätsmedizin Berlin, and Berlin Institute of Health, discussed the landscape for devices that forecast seizures, including the use of multi-modal wristband sensors.

Effect modification analysis showed that the treatment effect when using CBD was comparable between patients with and without infantile spasm history.

No patient with CDKL5 Deficiency Disorder developed valvular heart disease or pulmonary arterial hypertension while being treated with fenfluramine.

The safety profile of diazepam remained similar to what was previously observed, but generally, more patients in the concomitant benzodiazepine subgroup experienced more TEAEs.

The initial study results may provide the basis for future evaluation as a step towards patient empowerment and objective epilepsy diagnostics for broad application.

High retention rates and number of patients remaining seizure-free for prolonged periods indicated the efficacy of cenobamate in treating focal seizures.

Fenfluramine was particularly effective in reducing generalized tonic-clonic seizure frequency in patients with Lennox-Gastaut syndrome, with a push for regulatory submission in the future.

In non-demented patients with Parkinson disease, hippocampal subfields showed associations with memory, spatial working memory, language and executive functions, and CSF tau levels.

The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center sat down to discuss a multitude of topics surrounding Infantile Spasms Awareness Week.

The smartphone-delivered progressive muscle relaxation may be a useful and affordable form of evidence-based therapy that a primary care physician can prescribe to their patients.

The largest cohort to explicitly summarize the pregnancy-related characteristics of NMOSD with different antibody subsets demonstrated higher rates of annualized relapse during first trimester after delivery or abortion.

Rozanolixizumab was associated with reductions in anti-acetylcholine receptor autoantibodies and was well tolerated across 2 dose levels with no new safety findings.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

Evidence from 2 clinical trials were the basis of the biologics license application, with an FDA decision expected to be made by May 18, 2021.

An overview of the NeurologyLive tweet chat honoring National Epilepsy Awareness Month, featuring highlighted contributions from the medical community.

The GABAergic mechanism of sodium oxybate was able to increase simple movements in non-rapid eye movement sleep.

The vice president of Clinical Research at Eisai provides updates on the MOMENTUM trials which will examine lorcaserin as a potential treatment for patients with Dravet syndrome.

Frailty index score can identify patients at risk for cognitive dysfunction and might be an important marker with potential prognostic value.

The first trial of tranexamic acid in patients with known ongoing intracerebral hemorrhage shows insignificance compared with placebo, with future studies of simpler recruitment methods needed.